Results 41 to 50 of about 122,604 (290)

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

BMC Pharmacology and Toxicology, 2022
Background Tamoxifen treatment may induce dysregulation of estrogen homeostasis, leading to the occurrence of related adverse reactions. However, the potential mechanisms are still unclear.
Zhixiang Hao, Jiahao Xu, Han Zhao, Wei Zhou, Zhao Liu, Shiqing He, Xiaoxing Yin, Bei Zhang, Zhongjian Wang, Xueyan Zhou   +9 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

Tc-99m-tamoxifen: A novel diagnostic imaging agent for estrogen receptor-expressing breast cancer patients [PDF]

, 2022
PURPOSE The aim of the study was to radiolabel, characterize, and perform in vitro and in vivo assessment of Technetium-99m (Tc-99m) tamoxifen for screening ER expressing lesions in breast cancer patients.
Sharma, Uma, Upadhyay, Deepti, Vatsa, Rakhee, Mittal, Bhagwant Rai, Anupriya Chhabra, Deepti Upadhyay, Komalpreet Kaur, Jaya Shukla, Alka Bhatia, Chadha, Vijayta, Laroiya, Ishita, Bhatia, Alka, Bal, Amanjit, Vijayta Chadha, Gurpreet Singh, Kaur, Komalpreet, Shukla, Jaya, Amanjit Bal, Kumar, Rajender, Chhabra, Anupriya, Rajender Kumar, Bhagwant Rai Mittal, Singh, Gurpreet, Uma Sharma, Rakhee Vatsa, Ishita Laroiya   +25 more
core   +1 more source

The tamoxifen dilemma [PDF]

Carcinogenesis, 1999
The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. It could also play a role as a breast cancer chemopreventive agent. However, epidemiological studies in both tamoxifen-treated breast cancer patients and in healthy women have shown that ...
openaire   +2 more sources

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

BMC Ophthalmology, 2021
Background Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing
Chuanyu Li, Jun Xiao, He Zou, Bo Yang, Lifu Luo   +4 more
doaj   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Long-term effectiveness of adjuvant Goserelin in premenopausal women with early breast cancer [PDF]

, 2009
BACKGROUND: Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer.
Fornander, T, S. Forsyth, Johansson, Ulla,, T. Fornander, U. Johansson, Reczko, Krystyna,, B. Nordenskjold, Nordenskjold, Bo, Fornander, Tommy,, K. Reczko, Reczko, Krystyna, Fohlin, H, Hackshaw, Allan, Fornander, Tommy, Fohlin, Helena,, Valentini, Miriam,, H. Fohlin, Sainsbury, R, Fohlin, Helena, Johansson, U, Monson, Kathryn,, Reczko, K, M. Valentini, Forsyth, Sharon, Sainsbury, Richard,, Nicolucci, A, Monson, K, R. Sainsbury, Baum, M, Sainsbury, Richard, Valentini, Miriam, A. Hackshaw, Nordenskjöld, Bo,, Forsyth, Sharon,, M. Baum, A. Nicolucci, Nordenskjold, B, Fornander, T,, K. Monson, Johansson, Ulla, Nicolucci, Antonio,, Baum, Michael,, Baum, Michael, Hackshaw, Allan,, Hackshaw, A, Valentini, M, Monson, Kathryn, Nicolucci, Antonio, Forsyth, S   +48 more
core   +2 more sources